In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...
This analysis finds that 57.4 million adults under the age of 65 could potentially be eligible for GLP-1 drugs based on ...
Karla Robinson, MD and Medical Editor at GoodRx discusses how GLP-1 receptor agonists work and their benefits.
GLP-1 based drugs are transforming the treatment of obesity and opening up new avenues for addressing heart disease, ...
The demand for medications like Ozempic continues to cause shortages for both those seeking weight loss and patients with ...
A large swath of insured Americans could be eligible for a popular class of weight loss and diabetes drugs. Meanwhile, Apple ...
While drugmakers Novo Nordisk and Eli Lilly assert that shortages of popular weight loss and diabetes medications Wegovy, Ozempic, Mounjaro and Zepbound are easing, many patients continue to face ...
A Cleveland Clinic study showed that in patients with type 2 diabetes, obesity, and chronic kidney disease, bariatric surgery ...
Can a popular medication used to change your body also be affecting your mood? It’s a question that some users of semaglutide ...
Starting price of $149 offers improved accessibility compared to market prices of brand-name medications which can be 8x ...